Ilya Goldshleger Sells 3,100 Shares of RxSight, Inc. (NASDAQ:RXST) Stock

RxSight, Inc. (NASDAQ:RXST) insider Ilya Goldshleger sold 3,100 shares of RxSight stock in a transaction on Wednesday, October 16th. The stock was sold at an average price of $49.78, for a total transaction of $154,318.00. Following the sale, the insider now directly owns 42,246 shares of the company’s stock, valued at $2,103,005.88. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Ilya Goldshleger also recently made the following trade(s):

• On Friday, October 18th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,529.45.
• On Friday, October 11th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $50.19, for a total value of $155,589.00.
• On Monday, October 14th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $50.09, for a total value of $155,279.00.
• On Tuesday, October 8th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.26, for a total value of $149,606.00.
• On Friday, October 4th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $48.01, for a total transaction of $148,831.00.
• On Monday, September 30th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $49.02, for a total transaction of $151,962.00.
• On Thursday, September 26th, Ilya Goldshleger sold 3,105 shares of RxSight stock. The stock was sold at an average price of $49.29, for a total transaction of $153,045.45.
• On Monday, September 23rd, Ilya Goldshleger sold 3,100 shares of RxSight stock. The shares were sold at an average price of $52.67, for a total transaction of $163,277.00.
• On Friday, September 20th, Ilya Goldshleger sold 3,100 shares of RxSight stock. The stock was sold at an average price of $53.19, for a total value of $164,889.00.
• On Monday, August 5th, Ilya Goldshleger sold 9,000 shares of RxSight stock. The shares were sold at an average price of $39.25, for a total value of $353,250.00.

RxSight Stock Up 0.9 %

RxSight stock opened at $50.47 on Friday. RxSight, Inc. has a twelve month low of $20.66 and a twelve month high of $66.54. The company has a market capitalization of $1.87 billion, a P/E ratio of -40.06 and a beta of 1.20. The stock’s 50 day moving average is $52.12 and its 200 day moving average is $53.84.

RxSight (NASDAQ:RXST) last released its earnings results on Monday, August 5th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.06. The firm had revenue of $34.89 million for the quarter, compared to analysts’ expectations of $32.33 million. RxSight had a negative return on equity of 19.33% and a negative net margin of 31.92%. The company’s quarterly revenue was up 67.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.40) earnings per share. As a group, equities analysts expect that RxSight, Inc. will post -0.81 EPS for the current year.

Institutional Trading of RxSight

A number of institutional investors and hedge funds have recently bought and sold shares of RXST. CWM LLC lifted its stake in shares of RxSight by 727.5% in the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after buying an additional 371 shares in the last quarter. Quest Partners LLC purchased a new position in RxSight in the 2nd quarter worth approximately $41,000. Larson Financial Group LLC bought a new position in RxSight in the 1st quarter valued at approximately $51,000. Amalgamated Bank boosted its stake in RxSight by 21.3% during the 2nd quarter. Amalgamated Bank now owns 1,177 shares of the company’s stock valued at $71,000 after purchasing an additional 207 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new stake in shares of RxSight in the 2nd quarter worth $156,000. 78.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

RXST has been the subject of several recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $66.00 price objective on shares of RxSight in a research report on Friday, September 13th. Stifel Nicolaus dropped their price target on shares of RxSight from $70.00 to $65.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. Oppenheimer cut their price target on shares of RxSight from $72.00 to $65.00 and set an “outperform” rating on the stock in a report on Tuesday, August 6th. BTIG Research increased their target price on shares of RxSight from $72.00 to $73.00 and gave the stock a “buy” rating in a report on Monday, July 15th. Finally, Wells Fargo & Company reduced their price target on shares of RxSight from $68.00 to $54.00 and set an “overweight” rating on the stock in a research report on Tuesday, August 6th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $60.14.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.